FDA Approves First-Ever Gene Therapy for Treatment of Genetic Hearing Loss
The U.S. Food and Drug Administration today approved Otarmeni (lunsotogene parvec-cwha), the first-ever dual adeno-associated virus (AAV) vector-based gene therapy.
Summary not yet generated for this article.
Comments (96 of ) ⌛